GSK Stock Falls 2.75% Amid Increased Tax Pressure and Legal Relief, With Trading Volume Soaring 75% to Rank 373rd

Overview of GSK's Market Performance

On March 5, 2026, GlaxoSmithKline (GSK) experienced a 2.75% drop in its share price, accompanied by a trading volume of $380 million—a notable 75.41% surge compared to the previous session. This placed GSK at 373rd in trading activity among all listed stocks, indicating a moderate level of investor engagement. Despite recent legal and regulatory headlines, the downward movement in the stock price points to lingering market caution or possibly a wider downturn within the pharmaceutical industry.

Main Influences on GSK's Stock

GSK recently saw a securities fraud class action related to Zantac dismissed by the U.S. District Court for the Eastern District of Pennsylvania. The court ruled that the lawsuit was filed past the allowable timeframe, referencing publicly accessible information that should have prompted earlier action. Although this decision temporarily eases legal pressures for GSK, the court’s rationale highlights the significance of timely legal filings, potentially limiting future liabilities. However, investors may have hoped for a more decisive victory, and the dismissal did not fully alleviate broader concerns surrounding the company.

Another significant challenge arose from the implementation of global minimum tax rules, which led to a reduction in GSK’s tax benefits by £169 million ($226 million) for 2025. This was reported as a Pillar Two tax expense in the company’s annual statement, in line with the OECD’s 15% minimum corporate tax policy. This non-cash charge has a direct effect on GSK’s profitability and earnings per share, which could negatively influence investor outlook. The tax impact, combined with ongoing regulatory scrutiny in the pharmaceutical sector, likely contributed to the recent share price decline.

On a more positive note, GSK made progress in its drug development pipeline. The company obtained approvals from both the European Commission and Japan’s Ministry of Health for depemokimab (EXDENSUR) as an additional therapy for severe chronic rhinosinusitis with nasal polyps (CRSwNP). These regulatory achievements demonstrate GSK’s commitment to addressing unmet medical needs and strengthening its respiratory treatment offerings. However, the U.S. FDA declined to approve depemokimab for CRSwNP, without providing specific reasons, which introduces a degree of uncertainty. GSK remains optimistic about the drug’s prospects and intends to continue working with U.S. regulators, but the lack of approval could postpone potential revenue.

Strategic collaborations have also played a role in GSK’s growth initiatives. The company entered into a partnership with CAMP4 Therapeutics, securing $17.5 million upfront to support RNA-based drug discovery. Additionally, GSK received a $24.8 million payment from SCYNEXIS in the fourth quarter of 2025, related to the transfer of the BREXAFEMME New Drug Application, highlighting GSK’s involvement in advancing antifungal treatments. While these alliances foster innovation, the associated expenditures and ongoing research commitments may temporarily constrain financial flexibility.

Altogether, the combination of legal resolutions, regulatory hurdles, pipeline successes, and collaborative ventures creates a nuanced outlook for GSK. While the dismissal of the Zantac lawsuit and international drug approvals provide strategic benefits, the increased tax burden and unresolved U.S. regulatory issues present ongoing risks. Investors appear to be reassessing their positions, as reflected in the recent share price movements that balance these competing factors.